Literature DB >> 16145041

Taking down tumors: vascular disrupting agents entering clinical trials.

Leslie Harris O'Hanlon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16145041     DOI: 10.1093/jnci/dji298

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

Review 1.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

Authors:  Y Waerzeggers; R T Ullrich; P Monfared; T Viel; M Weckesser; W Stummer; O Schober; A Winkeler; A H Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 2.  A review on various targeted anticancer therapies.

Authors:  Junjie Li; Feng Chen; Marlein Miranda Cona; Yuanbo Feng; Uwe Himmelreich; Raymond Oyen; Alfons Verbruggen; Yicheng Ni
Journal:  Target Oncol       Date:  2012-02-15       Impact factor: 4.493

Review 3.  Molecular-targeted therapies for ovarian cancer: prospects for the future.

Authors:  Tamotsu Sudo
Journal:  Int J Clin Oncol       Date:  2012-08-23       Impact factor: 3.402

4.  Modulation of in vivo tumor radiation response via gold nanoshell-mediated vascular-focused hyperthermia: characterizing an integrated antihypoxic and localized vascular disrupting targeting strategy.

Authors:  Parmeswaran Diagaradjane; Anil Shetty; James C Wang; Andrew M Elliott; Jon Schwartz; Shujun Shentu; Hee C Park; Amit Deorukhkar; R Jason Stafford; Sang H Cho; James W Tunnell; John D Hazle; Sunil Krishnan
Journal:  Nano Lett       Date:  2008-04-16       Impact factor: 11.189

5.  Development of water soluble derivatives of cis-3, 4', 5-trimethoxy-3'-aminostilbene for optimization and use in cancer therapy.

Authors:  David E Durrant; Joanna Richards; Ashutosh Tripathi; Glen E Kellogg; Paolo Marchetti; Marco Eleopra; Giuseppina Grisolia; Daniele Simoni; Ray M Lee
Journal:  Invest New Drugs       Date:  2008-05-31       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.